

Title of Abstract	Abstract Code
SUPPRESSION OF NOS1 DERIVED NITRIC OXIDE DAMPENS MACROPHAGE FOAM CELL FORMATION AND ENDOTHELIAL DYSFUNCTIONING	O-CCK1
DISTURBED FLOW PROMOTES ENDMT AND ENDOTHELIAL DYSFUNCTION IN THE PATHOGENESIS OF VARICOSE VEINS	O-CCK2
COMBINATION OF COQ10 & OMEGA-3 SYNERGISES PROTECTIVE EFFECT ON VASCULAR PERMEABILITY IN STROKE	O-CCK3
DRUG REPURPOSING: LANSOPRAZOLE IN CARDIAC FIBROSIS	O-CCK4
CARDIOPROTECTIVE EFFECTS OF BETA VULGARIS EXTRACT AND L-ARGININE AGAINST ISOPRENALINE- INDUCED MYOCARDIAL INFARCTION IN RATS	O-CCK5
CANAGLIFLOZIN ATTENUATES CARDIAC HYPERTROPHY INDUCED BY ABDOMINAL AORTIC COARCTATION IN DIABETIC RATS AND THE AUGMENTED ANGIOTENSIN II AORTIC CONTRACTILE RESPONSES	O-CCK6
A COMMON PROMOTER HAPLOTYPE IN MATRIX METALLOPROTEINASE 8 GENE IS ASSOCIATED WITH INCREASED RISK FOR HYPERTENSION IN INDIAN POPULATIONS	O-CCK7
CYCLOPHILIN A EXPRESSION REDUCES ON YOGA INTERVENTION IN HYPERCHOLESTEROLEMIC INDIVIDUALS	O-CCK8
TOPIRAMATE: A NOVEL ANTIEPILEPTIC PROTECTS STREPTOZOTOCIN INDUCED SCIATIC NERVE LESION IN RAT MODEL OF DIABETIC NEUROPATHY	O-CCK9
FORMULATION, CHARACTERIZATION AND ACUTE TOXICITY STUDIES OF HERBAL ETHOSOMAL GEL FOR DIABETIC NEUROPATHY	O-CCK10
SIMULTANEOUS INHIBITION OF NEPRILYSIN AND ACTIVATION OF ACE2 PREVENTED DIABETIC CARDIOMYOPATHY	O-CCK11
ISCHEMIC RENAL INJURY-ASSOCIATED CARDIAC DYSFUNCTION IN DIABETIC AND NON-DIABETIC RATS: ROLE OF DEPRESSOR ARM OF RAS	O-CCK12
EVALUATION OF ANTI-OBESITY AND ANTI-HYPERLIPIDEMIC ACTIVITY OF COW URINE PREPARATIONS IN RAT MODELS	O-CCK13
PEROXIREDOXIN-3 GENE EXPRESSION IS REGULATED BY TRANSCRIPTION FACTORS NF-KB, CREB AND SP1 IN DIABETIC CARDIOMYOPATHY	O-CCK14
HYPERGLYCEMIA INDUCED DNA HYPERMETHYLATION OF ANTIOXIDANT GENES AND ITS ROLE IN THE PATHOGENESIS OF DIABETIC CARDIOMYOPATHY	O-CCK15
MOLECULAR DOCKING ANALYSIS OF ISOLATED PHYTOCHEMICALS FROM LEAVES OF OCIMUM SANCTUM AS POSITIVE MODULATORS IN POTENTIATING SK/IK CHANNEL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE	O-CCK16

Title of Abstract	Abstract Code
MANAGING HYPERTENSION BY TARGETING CYTOCHROME B5 REDUCATSE 3: A CONTEMPORARY THERAPEUTIC STRATEGY	O-SCT1
EFFECT OF TLR4 ANTAGONIST IN EXPERIMENTAL MODEL OF MYOCARDIAL INFARCTION	O-SCT2
CARDIOPROTECTIVE EFFECT OF AQUEOUS EXTRACT OF ARECA CATECHU EXTRACT AGAINST ISOPRENALINE INDUCED CARDIAC TOXICITY	O-SCT3
DECREASED EXPRESSION OF SCN5A GENE INVOLVED IN REMODELING OF CARDIOMYOBLAST: FOCUSING ON ENERGY METABOLISM	O-SCT4
ALLYL METHYL SULFIDE, AN ACTIVE METABOLITE OF GARLIC, AMELIORATES PRESSURE OVERLOAD-INDUCED CARDIAC HYPERTROPHY VIA MODULATION OF MITOCHONDRIAL DYNAMICS	O-SCT5
CARDIOPROTECTIVE POTENTIAL OF LIGANDS FROM AMALAKI RASAYANA IN MYOCARDIAL REMODELING: A MOLECULAR MODELING STUDY	O-SCT6
PROTECTIVE EFFECTS OF LYCOPENE ALONE AND ITS COMBINATION WITH OLIVE OIL IN DIABETES INDUCED NEUROPATHIC PAIN IN RATS	O-SCT7
NEPHROPROTECTIVE ACTIVITY OF LYCOPENE AND OLIVE OIL IN DIABETES INDUCED NEPHROPATHY IN RATS	O-SCT8
CARDIAC CHANNELOPATHIES: FROM ION CHANNEL TO BEDSIDE	O-SCT9
LIRAGLUTIDE PROTECTS AGAINST DIABETIC CARDIOMYOPATHY IN C57BL/6 MICE	O-DKA1
IN SILICO STUDIES OF SWERTIAMARIN AND ITS DERIVATIVES: IMPLICATION IN DESIGNING OF NOVELANTIDIABETIC DRUG	O-DKA2
DEVELOPMENT OF SUITABLE TOPICAL FORMULATION OF SILVER-NANOPARTICLE FOR WOUND INJURIES	O-DKA3
TO STUDY THE ANTIHYPERTENSIVE EFFECT OF GK4 IN SPONTANEOUSLY HYPERTENSIVE RATS	O-DKA4
THERAPEUTIC ROLE OF BROMELAIN COPPER NANOPARTICLES INDUCED PRECONDITIONING AGAINST DIABETES MELLITUS AND ASSOCIATED CARDIOVASCULAR DISORDER	O-DKA5
EFFECT OF GREEN TEA ON CIGARETTE SMOKE-INDUCED CARDIAC REMODELING IN MICE	O-DKA6
ANTIOXIDANT ACTION OF A MONOTERPENE PHENOL, CARVACROL, ON HG(II)-EXPOSED RAT AORTA	O-DKA7
A STUDY ON RELATIONSHIP BETWEEN BODY COMPOSITION, FITNESS VARIABLES AND PERFORMANCE OF CLUB LEVEL CRICKET PLAYERS	O-DKA8

Title of Abstract	Abstract Code
EFFECTS OF GREEN TEA POLYPHENOLS IN ANILINE HYDROCHLORIDE INDUCED CARDIOTOXICITY, SPLEENTOXICITY AND NEPHROTOXICITY IN RATS	O-DKA9
ANTI-HYPERCHOLESTEROLEMIC ACTIVITY OF A GREEN SEAWEED ULVA FASCIATA COLLECTED FROM RAMESHWARAM, SOUTHEAST COAST OF INDIA	O-DKA10
ATORVASTATIN INHIBITS HIGH FAT DIET AND ZYMOXAN A INDUCED ATHEROSCLEROSIS BY SUPPRESSING TLR-2 AND NF-KB EXPRESSION IN C57BL/6 MICE	O-DKA11
EVALUATION OF ANTI-OBESITY POTENTIAL OF FENOFIBRATE IN MONOSODIUM GLUTAMATE -INDUCED OBESITY IN WISTAR RATS	O-DKA12
NANOPARTICLES ELUTING STENTS FOR CORONARY INTERVENTION	O-DKA13
THE IMPACT OF HMGB1 ON NEUTROPHIL AND LYMPHOCYTES RATIO IN PRE-ECLAMPTIC PATIENTS	O-NKG1
ROLE OF DAMPs IN TYPE 2 DIABETES MELLITUS	O-NKG2
EFFECT OF SHORT TERM PLYOMETRIC EXERCISE TRAINING ON PULMONARY PARAMETERS IN YOUNG ADOLESCENTS	O-NKG3
A CROSS-SECTIONAL STUDY OF CORONARY HEART DISEASE, ITS ASSOCIATED CO- MORBIDITIES AND PHARMACOECONOMIC BURDEN IN DELHI-NCR	O-NKG4
IMPACT OF FIBER ENRICH POLYHERBAL COOKIES ON BLOOD GLUCOSE LEVEL: A PILOT STUDY IN HEALTHY SUBJECTS AND A CROSS-OVER STUDY IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE AND METABOLIC SYNDROME	O-NKG5
RISK FACTORS AND ANGIOGRAPHIC PROFILE OF YOUNG CORONARYARTERY DISEASE PATIENTS	O-NKG6
AN OBSERVATIONAL STUDY ON THE DRUG USAGE PATTERN AND POLYPHARMACY DRIFT IN CARDIOVASCULAR INPATIENTS AT A TERTIARY CARE TEACHING HOSPITAL	O-NKG7
EXERCISE AND TYPE 2 DIABETES MELLITUS: POTENTIAL ROLE OF NITRIC OXIDE	O-NKG8
MODULATION OF CHOLESTEROL EFFLUX CAPACITY (CEC) OF HIGH DENSITY LIPOPROTEIN (HDL) WITH BARIATRIC SURGERY	O-NKG9
EXPLORING THE FUNCTIONALITY OF HDL IN PATIENTS WITH ACUTE CORONARY SYNDROME	O-NKG10
PREVALENCE OF ALZHEIMER'S DISEASE, DEMENTIA AND MILD COGNITIVE IMPAIRMENT DISORDERS IN PATIENT SUFFERING FROM DIABETES MELLITUS HAVING CORONARY ARTERY DISEASES IN AHMEDABAD REGION	O-NKG11
EFFECT OF TOTAL FLAVONOID FRACTION FROM DRIED FRUIT OF PHOENIX DACTYLIFERA ON POSTMENOPAUSAL COMPLICATIONS IN VCD INDUCED OVOTOXICITY IN FEMALE RATS	O-ORS1

Title of Abstract	Abstract Code
FORMULATION DEVELOPMENT, EVALUATION AND COMPARISON OF DIFFERENT FORMULATIONS OF NAIL LACQUER FOR TREATMENT OF ONYCHOMYCOSIS	O-ORS2
GEL FORMULATION AND CHARACTERIZATION OF DRUG X AND EVALUATION OF ITS ANTI-PSORIATIC ACTIVITY	O-ORS3
POLYMER -LIPID HYBRID NANOVEHICLES DESIGNED FOR SYNERGISTIC DRUG DELIVERY FOR SOLID TUMOR MANAGEMENT	O-ORS4
CYTOPROTECTIVE ACTIVITY OF BERBERIS ARISTATA IN DMBA... INDUCED MODEL IN RODENTS	O-ORS5
STANDARDISATION OF BERBERINE, A-PINENE AND B PINENE USING HPTLC AND GCMS AND THEIR CYTOPROTECTIVE ROLE IN MOUSE MODEL	O-ORS6
FORMULATION AND EVALUATION OF CALCIUM FERROCYANIDE PEEL OFF GEL: A COMPETENT APPROACH FOR EXTERNAL DECORPORATION OF RADIONUCLIDES	O-ORS7
A COMPARATIVE MOLECULAR DOCKING STUDIES OF GENISTEIN ESTER DERIVATIVES IN POSTMENOPAUSAL DRY EYE SYNDROME & RELATION BETWEEN PMDED/ADDED AND HEART PATIENTS	P-NSD1
EFFECTS OF GAQ-RGS2 SIGNALING INHIBITOR IN AMINOPHYLLINE INDUCED CARDIAC ARRHYTHMIA	P-NSD2
TO INVESTIGATE THE ROLE OF HMGB1 IN HEMODYNAMICS OF L-NAME INDUCED PREECLAMPSIA IN EXPERIMENTAL ANIMALS.	P-NSD3
EFFECT OF PENTYLENETETRAZOLE(PTZ) KINDLING ON CARDIAC PARAMETERS AND ROLE OF ATENOLOL IN PREVENTING SUDDEN UNEXPECTED DEATH IN EPILEPTIC PATIENTS (SUDEP).	P-NSD4
DESIGN, SYNTHESIS OF 2-AMINOBENZOTHAZOLE DERIVATIVES AND IT'S BIOLOGICAL EVALUATION AS POTENT ANTI-OXIDANT ACTIVITY	P-NSD5
SIRTUIN ACTIVATION IMPROVES CARDIAC FUNCTION IN DIABETIC RAT THROUGH ENHANCING MITOCHONDRIAL BIOGENESIS	P-NSD6
DECIPHERING THE STRUCTURAL DETERMINANTS TO DESIGN THE SIRT1 SELECTIVE MODULATORS	P-NSD7
EVALUATION OF AMELIORATIVE EFFECT OF QUERCETIN AND CANDESARTAN IN ISOPROTERENOL INDUCED CARDIOTOXICITY	P-NSD8
THERAPEUTIC INTERVENTION FOR TREATMENT OF IRON OVERLOAD INDUCED CARDIOVASCULAR DISORDERS	P-NSD9
MATERNAL HYPERCHOLESTEROLEMIA INFLUENCES EXPRESSION OF LDL RECEPTORS AND TRANSPORTERS IN THE PLACENTA OF NEW ZEALAND WHITE RABBITS	P-NSD10

Title of Abstract	Abstract Code
CYCLOPHILIN A PROMOTES MACROPHAGE APOPTOSIS VIA MITOCHONDRIAL CASPASE ACTIVATION	P-NSD11
CURATIVE ACTIVITY OF JASMINUM SAMBAC ON EXPERIMENTALLY INDUCED CALCIUM OXALATE NEPHROLITHIASIS IN RAT MODEL	P-NSD12
A QUANTITATIVE STRUCTURE BASED DRUG DESIGN OF HUMAN ALDOSE REDUCTASE INHIBITORS AS ANTIDIABETIC AGENTS	P-NSD13
STRUCTURE BASED RATIONAL DRUG DESIGN OF CHOLINESTERASE INHIBITORS AS CARDIOVASCULAR MOLECULES	P-NSD14
INVESTIGATE THE ROLE OF ACUTE AND REPEATED STRESS ON REMOTE ISCHEMIC PRECONDITIONING AND ADENOSINE PRECONDITIONING INDUCED CARDIOPROTECTION IN RATS	P-NSD15
POTENTIAL ROLE OF GUT METABOLITE TRIMETHYLAMINE N-OXIDE AS A BIOMARKER IN PREDICTING NEUROLOGICAL AND CARDIOVASCULAR DISORDERS	P-NSD16
STRUCTURAL AND DYNAMICAL INSIGHTS OF FXR FOR THE DISCOVERY OF SMALL-MOLECULE AGONIST	P-NSD17
ANALYSIS OF CARDIOVASCULAR SAFETY PROFILE OF SOME COMMONLY PRESCRIBED ORAL HYPOGLYCEMIC AGENTS	P-NSD18
COMPARISON OF THE PACKAGE LEAFLETS AND THE SUMMARIES OF PRODUCT CHARACTERISTICS {SMPC} OF CARDIOVASCULAR DRUGS	P-PRS20
A VALIDATED LC-MS/MS METHOD FOR SIMULTANEOUS ESTIMATION OF DAPAGLIFLOZIN AND METFORMIN IN TABLET FORMULATION	P-PRS21
DESIGNING AND SYNTHESIS OF PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS ALK1 INHIBITOR PROMOTES CARDIOMYOGENESIS	P-PRS22
THE ROLE OF CYCLING AMP SIGNALING IN CARDIAC FIBROSIS	P-PRS23
RELATIONSHIP BETWEEN PHYSICAL ACTIVITY LEVELS AND HEART RATE VARIABILITY (HRV) AND MENTAL HEALTH IN YOUNG HEALTHY MALES	P-PRS24
PREPARATION AND EVALUATION OF MOUTH DISSOLVING TABLETS OF EBASTINE BY SUBLIMATION TECHNIQUE	P-PRS25
STEM CELL SOLUTION FOR ENHANCING ANGIOGENESIS AND WOUND HEALING	P-PRS26
NANOSTRUCTURED LIPID CARRIER LOADED WITH MACROLIDE ANTIBIOTIC	P-PRS27
ANTITUMOR ACTIVITY OF HYDROALCOHOLIC EXTRACT OF BERBERIS ARISTATA IN DMBA INDUCED MICE MODEL AND IN MCF7 BREAST CANCER CELL LINE	P-PRS28

Title of Abstract	Abstract Code
ANTI-TUMOR POTENTIAL OF BARTOGENIC ACID ALONE AND IN COMBINATION WITH PACLITAXEL USING HUMAN OVARIAN SKOV-3 XENOGRAFT MODEL	P-PRS29
APPLICATION OF ARTIFICIAL INTELLIGENCE IN PREVENTION OF MYOCARDIAL INFARCTION	P2-PRV1
ARTIFICIAL INTELLIGENCE HORIZON FOR PHARMACEUTICALS	P2-PRV2
FUTURE OF ARTIFICIAL INTELLIGENCE IN CARDIOLOGY: A GLIMPSE INTO FUTURE	P2-PRV3
ARTIFICIAL INTELLIGENCE: GROWING TOOL IN IDENTIFYING CARDIOVASCULAR DISEASES	P2-PRV4
ARTIFICIAL INTELLIGENCE IN CARDIOVASCULAR SCIENCES: A REVOLUTION IN HEALTHCARE	P2-PRV5
APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN CARDIOLOGY: FUTURE FOR CARDIOLOGY	P2-PRV6
VACCINE DEVELOPMENT AGAINST THE RENIN ANGIOTENSIN SYSTEM FOR THE TREATMENT OF HYPERTENSION	P2-PRV7
CRISPR CAS 9 (GENOME EDITING TECHNIQUE) - UPCOMING TECHNIQUE TO ALTER PCSK 9 GENE	P2-PRV8
PROTEIN KINASE R(PKR)-LIKE ENDOPLASMIC RETICULUM KINASE(PERK) INHIBITORS: A THERAPEUTIC LEAD FOR VARIOUS DISEASES	P2-PRV9
NON-CODING RNA IN CARDIOVASCULAR DISEASES	P2-PRV11
FUTURE ASPECTS OF GENE THERAPY	P2-PRV12
GENE TARGETED THERAPY AS A PROMISING TREATMENT FOR THE AMELIORATION OF CONGENITAL HEART DISEASE	P2-PRV13
ROLE OF MIRNA IN CARDIAC THERAPY	P2-PRV14
GENETIC TESTING – DIAGNOSTIC TOOL FOR CARDIOVASCULAR DISEASES	P2-PRV15
RECENT ADVANCES IN BIOSENSORS FOR CARDIOVASCULAR DISEASES	P2-PRV16
MEDICAL DEVICE REGULATION AND IMPACT OF NATIONAL PHARMACEUTICAL PRICING AUTHORITY: INDIAN PRSPECTIVE	P2-PRV17
CARDIOVASCULAR IMPLANTS: SUCCESS AND RISKS	P2-PRV18
LEADLESS PACEMAKER V/S TRADITIONAL PACEMAKER	P2-PRV19
MEDICAL DEVICE SOFTWARE: A REGULATORY ASPECTS IN EU AND USA	P2-PRV20
MEDICAL DEVICES: NEW AVENUE FOR PREVENTING CARDIOVASCULAR DISEASES (CVDS)	P2-PRV21
NOVEL CARDIO STENT TECHNOLOGY COST COMPARISON	P2-PRV22
COMPARATIVE STUDY OF CARDIOVASCULAR MEDICAL DEVICES REGULATIONS IN ASIAN COUNTRIES AND RECENT UPDATES	P2-PRV23
A REVIEW TO ANTIARRHYTHMIC DRUGS WITH CATHETER ABLATION THERAPY IN ATRIAL FIBRILLATION	P2-PRV24

<b>Title of Abstract</b>	<b>Abstract Code</b>
HEART MUSCLE BIOENGINEERING : A MODEL FOR REGENERATIVE MEDICINES	P2-PRV25
CARDIAC TISSUE ENGINEERING-AN EMERGING TRENDS	P2-PRV26
STEM CELL OF CARDIOVASCULAR SYSTEM	P2-PRV27
TREATMENT APPROACH IN CARDIOVASCULAR DISEASE VIA STEM CELL THERAPY	P2-PRV28
STEM CELLS IN CARDIOVASCULAR DISEASE: FROM CELL BIOLOGY TO CLINICAL THERAPY	P2-PRV29
GENERATION OF BIOARTIFICIAL HEARTS USING DECELLULARIZED SCAFFOLD & MIXED CELLS	P2-PRV30
OMICS APPROACH TO UNDERSTAND MOLECULAR DEFECTS IN HEARTS OF NEONATES DURING PREGESTATIONAL DIABETES	P2-PRV31
OMEGA 3- FATTY ACIDS IN PREVENTION OF CARDIOVASCULAR COMPLICATIONS	P3-PRV1
ROLE OF PYROPTOSIS ON CARDIAC MUSCLE CELL DAMAGE: A REVIEW	P3-PRV2
DIET-RELATED RISK FACTORS FOR HYPERLIPIDEMIA AND ATHEROSCLEROSIS	P3-PRV3
LET FOOD BE THY MEDICINE – ROLE OF FUNCTIONAL FOOD IN CARDIOVASCULAR DISEASES	P3-PRV4
THERAPEUTIC POTENTIAL OF DIETARY FLAVONOIDS IN THE PREVENTION OF CARDIOVASCULAR DISEASES	P3-PRV5
POTENTIAL APPLICATIONS OF NUTRACEUTICALS IN THE MANAGEMENT OF CARDIOVASCULAR DISORDERS: THE EMERGING EVIDENCES	P3-PRV6
CAN BREAKFAST OF OATS REPLACE YOUR ANTI-HYPERTENSIVE MEDICINE???	P3-PRV7
ISOLATED HEART PERFUSION TECHNIQUES FOR RAPID SCREENING OF MYOCARDIAL PRESERVATION METHODS	P3-PRV8
DRUG ABUSE INDUCED CARDIOVASCULAR TOXICITY AND ITS TREATMENT PARADISM	P3-PRV9
RECENT ADVANCEMENT IN TREATMENT OF CARDIAC DISEASE	P3-PRV10
EVALUATION OF NEUROPROTECTIVE AGENTS IN STROKE INDUCED BY BCCAO MODEL	P3-PRV11
SSRIS FOR THE TREATMENT OF DEPRESSION IN PATIENTS WITH ASSOCIATED CORONARY ARTERY DISEASE & CHRONIC HEART FAILURE ( PLEIOTROPIC EFFECTS OF SSRIS)	P3-PRV12
CURRENT STATUS OF CARDIOVASCULAR DRUGS IN INDIAN PHARMACOPOEIA AND NATIONAL FORMULARY OF INDIA	P3-PRV13
AYURVEDA MEDICINE MAKE USE ALWAYS THE TOP FIVE – SEVEN INGREDIENTS BUT NOW PRESENT TIME USE ALSO TRADITIONAL METHOD MORE UNNECESSARY INGREDIENTS	P3-PRV14
MANAGEMENT OF CARDIO VASCULAR DISEASE BY REDUCING STRESS WITH PRACTICING GRATITUDE AND JOY	P3-PRV15

Title of Abstract	Abstract Code
TRADITIONAL MEDICINAL APPROACHES AGAINST CHRONIC HEART DISEASES	P3-PRV16
USE OF NATURAL HERBS FOR THE MANAGEMENT OF HYPERTENSION	P3-PRV17
NATURAL NLRP3 INFLAMMASOME INHIBITORS AS A POSSIBLE FUTURE FOR MANAGEMENT OF CARDIOVASCULAR DISEASES (CVDS): A REVIEW	P3-PRV18
A COMPREHENSIVE REVIEW ON SMILAX ZEYLANICA	P3-PRV19
EXPLORING POTENTIAL OF HERBAL DRUGS IN TREATMENT OF HEART STROKE	P3-PRV20
MANAGEMENT OF ANGINA PECTORIS THROUGH HERBAL DRUGS	P3-PRV21
HYPERLIPIDEMIA: THE RISK FACTOR OF CARDIOVASCULAR DISEASE	P3-PRV22
METABOLIC SYNDROME: AN EPIDEMIC CAUSE FOR CARDIOVASCULAR DISEASES	P3-PRV23
INFLAMMATION: A MAJOR PLAYER IN THE DEVELOPMENT OF CARDIOMETABOLIC DISORDERS	P3-PRV24
CARDIOVASCULAR METABOLIC SYNDROME	P3-PRV25
ANGIOTENSIN TYPE 2 RECEPTOR AGONIST RESCUES OBESITY IN FEMALE MICES	P3-PRV26
TRANSLATIONAL DRUG AGAINST DIABETES AFFECTING HEART ACTIVITIES	P3-PRV27
BIOAVAILABILITY AND BIOEQUIVALENT STUDIES OF ANTI DIABETICS DRUGS	P3-PRV28
INFLAMMOSOMES IN DIABETES 22	P3-PRV29
PEDIATRIC HYPERTENSION	P4-PRV2
SYNTHESES OF SEVERAL ISATIN BASED MOLECULES WITH THEIR DIFFERENT PHARMACOLOGICAL APPLICATIONS AND STRUCTURAL ACTIVITY RELATIONSHIPS: A REVIEW	P4-PRV3
PREVALENCE OF HYPETENSION AND ITS CORRELATES IN HISAR (HARYANA) REGION	P4-PRV4
GESTATIONAL HYPERTENSION AND ASSOCIATED RISKS	P4-PRV5
ATRIAL NATRIURETIC PEPTIDE FACILITATES CARDIOPROTECTION OF ISCHEMIC PRECONDITIONING ON ISCHEMIA-REPERFUSION-CHALLENGED RAT HEART	P4-PRV6
ISCHAEMIA AND REPERFUSION- INDUCED MYOCARDIAL INJURY	P4-PRV7
A NEW ERA OF TRANSLATIONAL RESEARCH AGAINST IHD	P4-PRV8
ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE (INOCA): WOMAN HEART DISEASE	P4-PRV9
TREATMENT OF ANGINA PECTORIS	P4-PRV10
ASSOCIATING STAGES OF ENDOTHELIAL DYSFUNCTION WITH ENDOTHELIAL NITRIC OXIDE LEVELS AND ASSESSING ITS REVERSIBILITY	P4-PRV11



<b>Title of Abstract</b>	<b>Abstract Code</b>
PREVENTION OF CARDIOVASCULAR DISEASES BY HERBAL DRUGS	P4-PRV12
PREDICTION OF CARDIO VASCULAR DISEASE VIA C-REACTIVE PROTEIN LEVEL	P4-PRV13
OPTIMIZING HEALTH CARE AND OUTCOME IN WOMEN ON CVD	P4-PRV14
NEED OF CARDIOVASCULAR RISK SURVEILLANCE AND ASSOCIATED RISK FACTORS IN INDIANS	P4-PRV15
FAMILIAL HYPERCHOLESTEROLAEMIA AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE: AN UPDATED SYSTEMATIC REVIEW OF THE SCIENTIFIC EVIDENCE FROM OBSERVATIONAL STUDIES	P4-PRV16
SOME TREATMENT IN CARDIAC HEART FAILURE	P4-PRV17
DIASTOLIC DYSFUNCTION: LINKAGE BETWEEN HYPERTENSION AND HEART FAILURE	P4-PRV18
THE USE OF BIOMARKERS IN THE MANAGEMENT OF PATIENTS WITH HEART FAILURE HAS INCREASED TREMENDOUSLY OVER THE PAST DECADES	P4-PRV19
GREEN APPROACHES IN THE MANAGEMENT OF CARDIOVASCULAR DISORDERS	P4-PRV20
EFFECTS ON THE CARDIOVASCULAR SYSTEM DUE TO E-CIGARETTES	P4-PRV21
COMPARISON OF THE PACKAGE LEAFLETS AND THE SUMMARIES OF PRODUCT CHARACTERISTICS {SMPC} OF CARDIOVASCULAR DRUGS	P4-PRV22
GENETIC PHENOMENON AND ITS FUTURE ASPECTS REGARDING THE TREATMENT OF CARDIOVASCULAR DISEASES	P4-PRV23
COMPLEMENT SYSTEM - AN EMERGING THERAPEUTIC TARGET IN CARDIOVASCULAR DISEASES	P4-PRV24
NUCLEAR CARDIOLOGY FOR PROGNOSIS AND DIAGNOSIS OF HEART DISEASE	P4-PRV25
PREVALENCE OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS PATIENTS	P4-PRV26
DIABETIC CARDIOMYOPATHY: INSIGHTS INTO MOLECULAR MECHANISM, THERAPEUTIC TARGETS AND NATURAL REMEDIES	P4-PRV27
DIABETIC CARDIOMYOPATHY	P4-PRV28
COMBINED EFFECT OF VITAMIN D AND AEROBIC EXERCISES: CARDIOVASCULAR RISK FACTORS	P4-PRV29
THERAPEUTIC APPROACHES OF VARIOUS BIO-FERMENTED PRODUCTS IN THE TREATMENT OF PEPTIC ULCER	P5-PRS1
PHARMA OF NANO PARTICLE AS POTENTIAL AGENT FOR IMAGING AND DIAGNOSIS	P5-PRV2
NANOTHERANOSTICS: NEW REVOLUTION IN THE MANAGEMENT OF CARDIOVASCULAR DISEASES	P5-PRV4

<b>Title of Abstract</b>	<b>Abstract Code</b>
NANOBURRS- APPROACH TO TREAT CARDIOVASCULAR DISEASES	P5-PRV5
ENGINEERING PRECISION BIOMATERIALS: A NEW APPROACH FOR PERSONALIZED MEDICINE IN CARDIOVASCULAR HEALTHCARE	P5-PRV6
ETHOSOMES: A NOVEL PROSPECT IN TRANSDERMAL DRUG DELIVERY SYSTEM	P5-PRV7
PROTEIN PATCHES A NEW TECHNIQUE TO REGENERATE HEART MUSCLE	P5-PRV8
3D PRINTING IN PHARMACEUTICS: A NEW TOOL FOR DESIGNING CUSTOMIZED DRUG DELIVERY SYSTEMS	P5-PRV9
ROLE AND APPLICATION OF OF NANOTECHNOLOGY IN DRUG DELIVERY	P5-PRV10
EMERGING APPLICATIONS OF NANOMEDICINE FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES	P5-PRV11
NANOTECHNOLOGY: A NEW APPROACH TO CVDs	P5-PRV12
FROM BENCH TO BED SIDE: OPIUM ALKALOID - NOSCAPINE: A POTENTIAL CHEMOTHERAPEUTIC AGENT	P5-PRV13
PHARMACOLOGICAL TREATMENT OF PARKINSON DISEASE	P5-PRV14
ROLE OF JANUS KINASE IN RHEUMATOID ARTHRITIS	P5-PRV15
CARDIOVASCULAR COMPLICATIONS IN DIABETIC NEUROPATHY	P5-PRS16
EFFECTS OF GAQ-RGS2 SIGNALING INHIBITOR IN AMINOPHYLLINE INDUCED CARDIAC ARRHYTHMIA	P5-PRS17
DEVELOPMENT AND OPTIMIZATION OF NANO EMULGEL FORMULATION FOR PSORIASIS	P5-PRV18
MEDICAL DEVICES: NEW AVENUE FOR PREVENTING CARDIOVASCULAR DISEASES (CVDS)	P5-PRS19
DIABETIC FOOT SYNDROME AS A POSSIBLE CARDIOVASCULAR MARKER IN TYPE 2 DIABETIC PATIENTS	P5-PRV20
ARTIFICIAL INTELLIGENCE IN MANAGEMENT OF CARDIOVASCULAR HEALTHCARE	P5-PRV21
PHARMACOVIGILANCE: A WORLDWIDE MONITORING UNIT AND MASTER KEY FOR DRUG SAFETY AND REGULATIONS	P5-PRV22
NUTRACEUTICALS IN CARDIOVASCULAR DISEASE	P5-PRV23
EVALUATION OF NEUROPROTECTIVE EFFECT OF GARCINOL ON LPS INDUCED NURINFLAMMATION	P5-PRS24
<b>Important Note: Kindly see the Scientific Program for further details</b>	